Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

21.07 +0.34 (+1.64%)
Streaming Delayed Price Updated: 1:37 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025
The Company will Host a Conference Call and Webcast on Thursday, November 6, 2025, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
What Does the Market Think About Catalyst Pharmaceuticals Inc?
 
Via Benzinga
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Value Investment with Strong Fundamentals
Catalyst Pharmaceuticals (CPRX) appears undervalued with strong financials: zero debt, high profitability, and robust growth, making it a compelling value investing candidate. 
Via Chartmill
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Presents a Compelling Case for Affordable Growth
Discover Catalyst Pharmaceuticals (CPRX): a high-growth biotech stock with strong profitability, a solid balance sheet, and an attractive valuation. 
Via Chartmill
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Value Investing Opportunity with Strong Fundamentals
Catalyst Pharmaceuticals (CPRX) is a value investing candidate with strong fundamentals, low P/E ratios, robust financial health, high profitability, and impressive growth in the rare disease sector. 
Via Chartmill
How Is The Market Feeling About Catalyst Pharmaceuticals?
 
Via Benzinga
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top GARP Investment with Strong Growth and Reasonable Valuation
Catalyst Pharmaceuticals (CPRX) is a top GARP stock with strong growth, excellent profitability, and an attractive valuation, making it a compelling long-term investment. 
Via Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Stands Out as a High-Quality Caviar Cruise Candidate
Catalyst Pharmaceuticals (CPRX) excels in growth, profitability, and financial health, making it a top-quality stock for long-term investors according to the Caviar Cruise screen. 
Via Chartmill
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Value Investment in Biotech
Catalyst Pharmaceuticals (CPRX) is a strong value stock with low P/E ratios, high profitability, zero debt, and impressive growth, offering a solid margin of safety. 
Via Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Top Affordable Growth Stock with Strong Fundamentals
Catalyst Pharmaceuticals (CPRX) offers strong growth, fair valuation, and solid financials, making it a top pick for investors seeking affordable growth in biotech. 
Via Chartmill
Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Fits Louis Navellier’s Growth Investing Strategy with Strong Earnings Momentum and Rising Sales
Louis Navellier’s growth investing strategy highlights stocks like Catalyst Pharmaceuticals (CPRX), which shows strong earnings momentum, rising sales, and high profitability. CPRX meets key criteria,... 
Via Chartmill
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Growth Stock with Breakout Potential
Combine technical & fundamental analysis to spot growth stocks like Catalyst Pharmaceuticals (CPRX), showcasing strong financials & breakout potential. 
Via Chartmill
Is the Market Bullish or Bearish on Catalyst Pharmaceuticals?
 
Via Benzinga
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) – A Value Stock with Strong Fundamentals and Growth Potential
Catalyst Pharmaceuticals (CPRX) is a value stock with strong fundamentals—low P/E, zero debt, high profitability, and robust growth, making it a standout in biotech. 
Via Chartmill
Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
The Company will Host a Conference Call and Webcast on Thursday, August 7, 2025, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - A Strong Contender in Affordable Growth Stocks
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and reasonable valuation, making it a standout in affordable growth stocks. 
Via Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - A Strong Contender for Growth Investors
Catalyst Pharmaceuticals (CPRX) meets Louis Navellier's growth criteria with strong earnings, sales growth, and high profitability, making it an attractive stock for growth investors. 
Via Chartmill
Peering Into Catalyst Pharmaceuticals's Recent Short Interest
 
Via Benzinga
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Growth Stock with Technical Breakout Potential
CATALYST PHARMACEUTICALS (CPRX) shows strong growth, profitability, and a promising technical setup, making it a stock to watch. 
Via Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - A Rare Biotech With Undervalued Potential
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, profitability, and financial health at an undervalued price, making it a rare biotech stock for value investors. 
Via Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender in Affordable Growth Stocks
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth stocks. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.